ARCHIVES

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

ACCC Honors Hammond, Murphy

October 19, 2001

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

Harkin, Hatfield Propose Trust Fund to Raise Research Funding

May 28, 1993

Biological Modifiers Journal Objects To NEJ Policy, Says It Will OK Clinical Data Release

April 26, 1985

Surveillance Colonoscopy Cost-Effective For High-Risk

July 30, 2010

NCI To Commit $10 Million For SBIR Phase II Bridge Awards.

June 20, 2008